Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1% - Here's What Happened

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report)'s stock price fell 1% during mid-day trading on Friday . The stock traded as low as $0.50 and last traded at $0.50. 2,161,888 shares traded hands during mid-day trading, an increase of 100% from the average session volume of 1,082,880 shares. The stock had previously closed at $0.51.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. HC Wainwright upped their target price on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. D. Boral Capital cut their price objective on Lineage Cell Therapeutics from $3.00 to $2.00 and set a "buy" rating for the company in a report on Wednesday, November 20th.

Lineage Cell Therapeutics Stock Performance

The firm has a market capitalization of $110.21 million, a P/E ratio of -4.17 and a beta of 1.16.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in shares of Lineage Cell Therapeutics by 13.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company's stock valued at $613,000 after purchasing an additional 82,864 shares in the last quarter. Barclays PLC increased its position in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company's stock worth $192,000 after buying an additional 159,924 shares during the last quarter. Geode Capital Management LLC raised its holdings in Lineage Cell Therapeutics by 2.3% during the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company's stock valued at $3,331,000 after buying an additional 83,274 shares in the last quarter. State Street Corp lifted its position in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company's stock worth $2,361,000 after buying an additional 45,483 shares during the last quarter. Finally, Raffles Associates LP boosted its stake in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company's stock worth $4,081,000 after acquiring an additional 150,000 shares in the last quarter. Institutional investors own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.